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Abstract
Led by key opinion leaders in the field, the 25th Annual Meeting of the International Society for Biological Therapy
of Cancer (iSBTc, recently renamed the Society for Immunotherapy of Cancer, SITC) provided a scientific platform
for ~500 attendees to exchange cutting-edge information on basic, clinical, and translational research in cancer
immunology and immunotherapy. The meeting included keynote addresses on checkpoint blockade in cancer
therapy and recent advances in therapeutic vaccination against cancer induced by Human Papilloma Virus 16.
Participants from 29 countries interacted through oral presentations, panel discussions, and posters on topics that
included dendritic cells and cancer, targeted therapeutics and immunotherapy, innate/adaptive immune interplay
in cancer, clinical trial endpoints, vaccine combinations, countering negative regulation, immune cell trafficking to
tumor microenvironment, and adoptive T cell transfer. In addition to the 50 oral presentations and >180 posters
on these topics, a new SITC/iSBTc initiative to create evidence-based Cancer Immunotherapy Guidelines was
announced. The SITC/iSBTc Biomarkers Taskforce announced the release of recommendations on immunotherapy
biomarkers and a highly successful symposium on Immuno-Oncology Biomarkers that took place on the campus of
the National Institutes of Health (NIH) immediately prior to the Annual Meeting. At the Annual Meeting, the NIH
took the opportunity to publicly announce the award of the U01 grant that will fund the Cancer Immunotherapy
Trials Network (CITN). In summary, the Annual Meeting gathered clinicians and scientists from academia, industry,
and regulatory agencies from around the globe to interact and exchange important scientific advances related to
tumor immunobiology and cancer immunotherapy.
Guiding Cancer Immunotherapy from Bench to
Bedside
The opening scientific presentation–the Richard V.
Smalley, MD Memorial Lectureship–was delivered by
James P. Allison, PhD (Memorial Sloan-Kettering Can-
cer Center), a pioneer in the development of CTLA-4
blockade. Dr. Allison presented data on new insights
and opportunities in checkpoint blockade. He outlined a
number of key points to be addressed for further clinical
development of anti-CTLA-4, including better under-
standing cellular and molecular mechanisms, identifying
characteristics that distinguish responders from non-
responders, and determining the best conventional
therapies or vaccines to combine with CTLA-4 blockade
to improve outcomes in patients with cancer.
Dendritic Cells in Cancer
Carl G. Figdor, PhD (Nijmegen Centre for Molecular
Life Sciences) and Pawel Kalinski, MD, PhD (University
of Pittsburg Cancer Institute) co-chaired the first
plenary session on dendritic cells (DCs) and cancer.
Dr. Figdor addressed achievements, obstacles, and future
perspectives of DC vaccination. Progress in active
immunotherapy of prostate cancer with the autologous
cellular immunotherapy Sipuleucel-T was reported by
David L. Urdal (Dendreon Corporation). Bart Neyns,
MD, PhD (Universitair Ziekenhuis Brussel) presented on
therapeutic vaccination with mRNA-electroporated
autologous DCs in patients with advanced melanoma.
* Correspondence: FMarincola@mail.cc.nih.gov
1Society for Immunotherapy of Cancer, Milwaukee, WI, USA
Full list of author information is available at the end of the article
Balwit et al. Journal of Translational Medicine 2011, 9:60
http://www.translational-medicine.com/content/9/1/60
© 2011 Balwit et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.Andrew N. Cornforth, PhD (Hoag Memorial Hospital
Cancer Center) presented data that demonstrate that
resistance to the proapoptotic effects of IFN-g on mela-
noma cells used in patient-specific DC immunotherapy
is associated with improved overall survival. Research
conducted and reported by Jamie L. Harden (State Uni-
versity of New York, University at Buffalo) suggests that
IFN-gamma is central to both immunogenic and tolero-
genic properties of DCs after IL-12 and GM-CSF micro-
sphere treatment. Dr. Kalinski concluded the session
with a presentation on polarized (high IL-2 producing)
DCs in the immunotherapy of established cancer, in
which he reviewed data indicating that aDC1s preferen-
tially attract naïve effector and memory T cells rather
than Tregs and that this subset is more efficient in
inducing tumor-specific CTLs than standard DCs.
Dr. Kalinski presented results that demonstrate that
aDC1s induce CTL effector functions and responsive-
ness to tumor-produced chemokines in naïve and rest-
ing memory CD8
+ T cells. Moreover, vaccines from
aDC1s can be generated from patients with a large vari-
ety of cancers.
Targeted Therapeutics and Immunotherapy
Mary L. Disis, MD (University of Washington) and
Keiran S. Smalley, PhD (H. Lee Moffitt Cancer &
Research Institute) co-chaired a session on targeted
therapeutics and immunotherapy. Dr. Disis started the
session with a presentation on immune modulation of
breast cancer. She presented data from animal models
in which the development of breast cancer was inhibited
by immunization against a limited number of biologi-
cally relevant antigens. While subclinical disease may
limit protection, combination chemoprevention may
enhance vaccine efficacy. Dr. Disis concluded that vac-
cine strategies may benefit from targeting proteins
involved in oncogenesis.
Dr. Smalley reported on overcoming BRAF inhibitor
resistance in melanoma, noting that pERK recovers with
higher doses of PLX4720, potentially limiting the drug’s
effects. Low-level pERK signaling appears important for
a small subpopulation of cells to escape therapy. Dual
BRAF-MEK inhibition, he concluded, may limit escaping
cells.
Kim A. Margolin, MD (University of Washington,
Seattle Cancer Care Alliance) reported on results from
the “SELECT” trial of high-dose IL-2 treatment of
patients with metastatic renal cell carcinoma. In this
trial, the response rate with high-dose IL-2 was signifi-
cantly higher than historically achieved, likely related to
differences in patient selection. Dr. Margolin noted that
clinical and pathologic characteristics may help identify
patients who are unlikely to benefit from high-dose IL-2
treatment. Pathology review and staining for CA-IX in
this trial, however, did not improve selection of patients
who benefited from treatment.
Chunsheng Li, PhD (Ovarian Cancer Research Center,
University of Pennsylvania) discussed in vivo modeling
and detection of ovarian cancer vascular marker TEM1,
which was observed in 99% of ovarian cancer specimens
studied. This vascular model, Dr. Li suggested, can serve
as a platform both for studying the function of tumor
vascular markers and for testing new diagnostics and
therapeutic agents against tumor vasculature in vivo.
Innate/Adaptive Immune Interplay in Cancer
Vincenzo Cerundolo, MD, PhD (University of Oxford,
Institute of Molecular Medicine) and Laurence Zitvogel,
MD, PhD (Institute Gustave Roussy) co-chaired a ses-
sion on the interplay between innate and adaptive
immunity in cancer. Dr. Cerundolo addressed the role
of invariant NKT (iNKT) cells at the interface of innate
and adaptive immunity, noting that incubating neutro-
phils with serum amyloid A (SAA), which is secreted by
a large proportion of tumor-associated macrophages
(TAM) and primary melanoma cells, facilitates their
cross-talk with iNKT cells, leads to iNKT cell activation
and reduces IL-10 secretion. Dr. Cerundolo highlighted
the need to further explore and exploit the capacity of
iNKT cells to reduce the immunosuppressive activity of
neutrophils in melanoma.
Khashayarsha Khazaie, PhD, DSc (Northwestern Uni-
versity, Robert Lurie Comprehensive Cancer Center)
presented on the role of Tregs in colon cancer, high-
lighting observations that were consistent with Tregs
playing an anti-inflammatory and protective role in col-
orectal cancer, which can be compromised through
interactions with mast cells over the course of the dis-
ease. These results suggest that cross-talk between mast
cells and Tregs determines the level of inflammation in
colorectal cancer.
Bethany Mundy (The Ohio State University) discussed
myeloid-derived suppressor cells (MDSCs) and
decreased IFN responsiveness in tumor-bearing mice,
demonstrating that MDSCs inhibited IFN response via
nitration of STAT1 in tumor-bearing mice and that
MDSC depletion from tumor-bearing mice restored the
IFN response.
Laurence Zitvogel, MD, PhD (Institute Gustave
Roussy, INSERM France) presented on NKp30 isoforms
as a novel predictor of response to tyrosine kinase inhi-
bitors. Dr. Zitvogel reviewed functional differences in
the isoforms: DC/NK or NK/tumor cross-talk induces
IL-10 with the NKp30c isoform and IFNg with isoforms
NKp30a and NKp30b. Clustering of the NKp30 tran-
scriptional profiles could be used to discriminate
between responders and non- responders to Gleevec for
gastrointestinal stromal tumors, with less than 20% of
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relapse among non-responders with profile B.
Clinical Trial Endpoints
Vernon K. Sondak, MD (H. Lee Moffitt Cancer Center)
and F. Stephen Hodi, MD (Dana-Farber Cancer Insti-
tute) co-chaired a session on clinical trial endpoints.
Dr. Sondak reviewed endpoints and clinical trial designs
in historical studies on melanoma and recent results
with ipilimumab. He emphasized that progress in the
systemic therapy of metastatic melanoma requires well-
designed, well-executed phase III trials using agents
appropriately selected in phase II studies, and that elig-
ibility criteria, patient selection and study size account
for a large percentage of the variation in outcomes in
phase II trials. He suggested that six-month progres-
sion-free survival (PFS) and 12-month overall survival
(OS) may be better “selection” endpoints for phase II
trials in melanoma than objective response or median
survival. New trial designs, such as adaptive randomiza-
tion, and careful and individualized selection of end-
points are going to be necessary to evaluate the
increasing number of promising agents in melanoma
and other malignancies.
Dr. Hodi presented on immune-related response cri-
teria (irRC) noting the challenges of cancer immu-
notherapy clinical trial endpoints, including the
observation that activation and proliferation of immune
cell begins early and that immunotherapy effects on
tumors may take weeks to months to develop. More-
over, effects of immunotherapy on survival may take
years to assess. These responses are further complicated
by variability in cellular immune assays and the potential
for slow onset and late clinical effects from immu-
notherapy. Using CTLA-4 blockade with ipilimumab as
a platform, Dr. Hodi discussed the modification of anti-
tumor response endpoints to incorporate late onset of
clinical activity (i.e., response after progression), which
is common with CTLA-4 blockade in melanoma.
Lawrence Fong, MD (University of California, San
Francisco) focused on defining response in prostate can-
cer immunotherapy. While OS remains the definitive
outcome for defining clinical efficacy in prostate cancer,
it is not be feasible for early trial development. Immu-
notherapies that induce clinical responses in prostate
cancer provide the opportunity to help redefine mean-
ingful immune “responses.” Dr. Fong concluded that
clinical endpoints that allow for early progression are
being used in prostate cancer trials (e.g., Prostate Cancer
Clinical Trials Working Group) and should be applied
to immunotherapy trials in prostate cancer. Moreover,
immune correlates need to be validated in larger trials
(with clinical benefit), including Phase 3 clinical trials
that are followed for overall survival.
Annick Van den Abbeele, MD (Dana-Farber Cancer
Institute) discussed a new paradigm in cancer imaging
(i.e., metabolic imaging). Dr. Van den Abbeele noted
that in the future, cancer imaging will not rely solely on
measurement of tumor size, but rather will employ a
multiparametric approach designed to interrogate cellu-
lar and molecular events in tumor cells, the immune
system, and within the tumor microenvironment. Future
cancer imaging will provide information on the mechan-
ism of action of novel therapies and will provide quanti-
tative, noninvasive, pharmacodynamic information on
tumor metabolism.
Cancer Immunotherapy Guidelines: A New iSBTc/
SITC Initiative
In a special session, Howard L. Kaufman, MD (Rush Uni-
versity Medical Center) announced a new iSBTc/SITC
initiative: the development of cancer immunotherapy
guidelines. These guidelines will provide evidence-based
criteria for defining the clinical indications for immu-
notherapy and provide suggestions for when and how to
use immunotherapy in patients with cancer. A multi-
disciplinary task force is collecting and reviewing current
literature to make recommendations. These recommenda-
tions will be developed into a manuscript and the guide-
lines will be made available to the public through the
society’s web site.
Immunotherapy of High Risk HPV Infections
Cornelius J.M. Melief, MD, PhD (Leiden University
Medical Center) provided the second keynote address
on therapeutic vaccination against HPV16-induced dis-
ease. Dr. Melief presented data that demonstrate that
short peptide vaccines are not effective in therapeutic
vaccines against HPV16-induced cancer; long peptide
vaccines that harbor both CD4 and CD8 T cell epitopes
and require DC processing, however, are quite efficient.
Further improvements are possible by adding TLR
ligands or by conjugating TLR ligands to the long pep-
tides. Dr. Melief suggested development of combination
treatment with long peptide vaccination, immunogenic
chemotherapy and inhibitors of checkpoint control
(CTLA-4 blocker, PD-1, PD-L1 blockers) for maximally
effective cancer treatment. He also suggested local deliv-
ery of mAb treatments in slow release formulation close
to tumor-draining lymph nodes to reduce toxicity.
Vaccine Combinations
Pierre Coulie, MD, PhD (de Duve Institute and Univer-
sité Catholique de Louvain) and Victor H. Engelhard,
PhD (University of Virginia School of Medicine) co-
chaired a session on vaccine combinations. Dr. Coulie
addressed the numbers and functions of lymphocytes in
human melanoma metastases. Vaccine trials in metastatic
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administered as peptides, proteins, peptide-pulsed DCs,
and recombinant poxviruses. Among patients who dis-
played tumor regression (10% - 20%), the number of
anti-vaccine CTLs was low. Further analysis indicated
that tumor regression was linked with activation of CTLs
that recognize other tumor-specific antigens not included
in the vaccine, and that some of these CTLs were in the
blood and tumors prior to vaccination. New CTLs
appeared following vaccination. These included both new
clones against antigens targeted prior to vaccine adminis-
tration (i.e., clonal spreading) and new clones against pre-
viously ignored antigens (i.e., antigen spreading). Dr.
Coulie suggested that melanoma patients spontaneously
mount anti-tumor CTL responses that become inefficient
at rejecting the tumor due to local immunosuppression
or reduced tumor antigen expression. Vaccination may
activate a small number of anti-vaccine CTLs, which
upon trafficking to the tumor, may relieve suppression
and promote activation of many other anti-tumor CTLs
that contribute to tumor regression.
Victor H. Engelhard, PhD (University of Virginia
School of Medicine) discussed immunological proteo-
mics, the identification of phosphorylated peptide anti-
gens displayed on cancer cells, and prospects for their
use as immunotherapeutics. Dr. Engelhard noted that
few of the currently identified melanoma Ags are from
proteins associated with transformation and/or metasta-
sis. Identification of Ags from proteins associated with
control of cell growth, survival or metastasis may be
useful because alteration of these essential proteins asso-
ciated with immune evasion may comprise survival of
the tumor cell.
Phosphorylation of signaling molecules regulates acti-
vation and proliferation of many cancers. Dr. Engelhard
and colleagues have developed a strategy to identify
MHC-associated peptides modified by intracellular
phosphorylation using mass spectrometry. This has
allowed isolation of a small number of peptides that are
associated with cellular transformation or metastasis. As
a candidate for immunotherapy, the phosphopeptide
should be expressed on melanomas from multiple
patients, with little or no expression on normal cells. It
should be associated with an aspect of malignancy and
must be immunogenic. Ideally, it would be expressed on
other kinds of cancer cells as well. Phosphopeptides
associated with melanoma are immunogenic. Phospho-
peptide-specific CD8 T cells differentiate between the
phosphorylated and non-phosphorylated peptides and
recognize melanoma cells. Dr. Engelhard and colleagues
have recently demonstrated that the phosphate moiety is
readily accessible for direct interaction with the TCR
and the MHC molecule, increasing the peptides affinity
and modifying its conformation. Thus, phosphorylation
can generate new Ags. MHC-restricted phosphopeptides
warrant further investigation as potential targets for
melanoma immunotherapy.
Hideho Okada, MD, PhD (University of Pittsburgh
Cancer Institute) presented on the induction of CD8
+ T
cell responses against novel glioma-associated antigen
(GAAs) peptides and clinical activity by vaccinations with
aDC1s and Poly-ICLC in patients with recurrent malig-
nant glioma. The first four vaccines induced positive
immune responses against at least one of the targeted
GAAs in 11 of 19 patients, with booster vaccination lead-
ing to positive responses in an additional four patients.
Type 1 cytokines and chemokines were up-regulated and
eight patients experienced progression free status ≥12
months; one patient with recurrent glioblastoma multi-
forme achieved sustained clinical response. IL-12 produc-
tion by aDC1s correlated positively with PFS.
Jedd D. Wolchok, MD, PhD (Memorial Sloan-Kettering
Cancer Center) discussed endogenous and exogenous
vaccination in the context of immunologic checkpoint
blockade. Dr. Wolchok reviewed data that demonstrate
that CTLA-4 blockade with ipilimumab results in pro-
longed survival of patients with refractory melanoma.
Moreover, clinical response has been associated with
changes in absolute lymphocyte count, NY-ESO-1 immu-
nity, and induction of ICOS expression on CD4
+ T cells.
These responses require prospective evaluation in
ongoing clinical trials. Indeed, the tumor microenviron-
ment remains fertile ground to study the mechanism
underlying immunologic checkpoint blockade.
Saskia J. Santegoets, PhD (VU University Medical
Center) presented on T cell activation, PSMA serocon-
version and increased Th17 rates associated with favor-
able clinical outcome in prostate cancer patients treated
with prostate GVAX and anti-CTLA-4 immunotherapy.
Dr. Santegoets reported that treatment was associated
with induction of T cell activation and that rates of
Tregs increased in patients with progressive disease
(PD), but not in those with partial response (PR) or
stable disease (SD). Indeed, elevations in Treg levels
were associated with reduced survival. Treatment with
GVAX/ipilimumab led to Th17/Th2 polarization, with
Th17 induction coinciding with the onset of immune-
related adverse events and a decline in PSA, and induc-
tion of Th2 associated with better OS. Dr. Santegoets
reported serological PSMA responses associated with
treatment and that PSMA seroconversion was associated
with improved OS.
Willem W. Overwijk, PhD (University of Texas, MD
Anderson Cancer Center) presented data suggesting that
vaccine sites can serve as sinks and become a “grave-
yard” for tumor-specific T cells. Dr. Overwijk’sr e s u l t s
indicate that oil-based, long-lived vaccine formulations
activate T cells, but eventually tolerize the cells. While
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vants, oil-based vaccines tend to sequester T cells at the
vaccine site and limit T cell accumulation in the tumor.
Thus, long-lived vaccines can induce sub-optimal anti-
tumor immunity. Water-based, short-lived vaccine for-
mulations require additional adjuvants to activate T
cells, but do not tend to sequester T cells at the vaccine
site. Consequently, these formulations allow T cell accu-
mulation in the tumor and may have greater therapeutic
efficacy than long-lived formulations. Thus short-lived
vaccine formulations warrant further evaluation.
Antoni Ribas, MD (University of California, Los
Angeles) presented final efficacy results of A3671009, a
phase III study of tremelimumab versus chemotherapy
(dacarbazine or temozolomide) in first-line patients with
unresectable melanoma. Compared with chemotherapy,
tremelimumab resulted in a nonsignificant improvement
in survival. The duration of first objective tumor responses
to tremelimumab was significantly longer than responses
to chemotherapy. A low baseline level of C reactive pro-
tein (CRP) and a baseline absolute lymphocyte count in
the normal range selected for patients with higher tumor
response rate and better survival outcome with tremelimu-
mab compared with chemotherapy, which may reflect an
interaction between the tumor microenvironment, tumor
inflammation, and an adaptive immune response.
Presidential Abstract Session
Based on the high quality of the data as reviewed by a
special committee, four abstracts from young investiga-
tors were selected for presentation during the presiden-
tial abstract session, chaired by iSBTc/SITC President
Bernard A. Fox, PhD (Earle A. Chiles Research Insti-
tute). Robbert Spaapen, PhD (University of Chicago)
presented results that indicate that interferon-b secre-
tion in the tumor microenvironment can cause potent
tumor control through host cells independently from
adaptive immunity. Results reviewed by Michael A. Cur-
ran, PhD (Memorial Sloan-Kettering Cancer Center)
demonstrate that 4-1BB activation induces the master-
regulator EOMES and a broad-spectrum Th1 phenotype,
which synergizes with CTLA-4 blockade to reject B16
melanoma. Evripidis Lanitis, BS (University of Pennsyl-
vania) indicated that ovarian cancer cells ubiquitously
express HER-2, and that even very low levels of HER-2
can lead to specific recognition by genetically redirected
T cells. Chao Ma, MS (California Institute of Technol-
ogy) presented on large-scale profiling of circulating
serum markers, single cell polyfunctionality and antigen
diversity of T cell response against melanoma.
Countering Negative Regulation
Pierre van der Bruggen, PhD (Ludwig Institute for Can-
cer Research) and Weiping Zou, MD, PhD (University
of Michigan) co-chaired a session exploring approaches
to counter negative regulation of anti-tumor T cell
responses. Dr. van der Bruggen addressed the possibility
of correcting the impaired function of human TILs.
While the identification of human tumor-specific Ags
has allowed the development of numerous cancer vac-
cine strategies, these approaches have shown low clinical
efficacy in melanoma patients, in part because of the
immunosuppressive environment of the tumor. In con-
trast to circulating CD8
+ blood cells, CD8
+ TILs demon-
strated impaired ex vivo IFN-g secretion due to
decreased TCR mobility upon trapping within a galec-
tin-3 clustered glycoprotein lattice. IFN-g secretion
could be restored by treating the TILs with a galectin
ligand N-acetyllactosamine (LacNAc). Dr. van der Brug-
gen discussed the hypothesis that activation of TILs may
modify the N-glycosylation pathway and the structure of
surface expressed N-glycans to enhance binding of
galectin-3, which is abundant in many solid tumors,
thereby impairing TCR mobility. Soluble competitive
ligands (e.g., anti-galectin-3 Ab) may restore TCR mobi-
lity and boost IFN-g secretion. A plant-derived polysac-
charide in clinical development has the capacity to
detach galectin-3 from CD8
+ and CD4
+ TILs and
increase their IFN-g production ex vivo.I nam o u s e
model, half of tumor-bearing mice that were vaccinated
with tumor Ag and received the polysaccharide rejected
the tumor, whereas the polysaccharide alone had no
benefit, suggesting the value of exploring combinations
of galectin-3 ligands with therapeutic cancer vaccines in
clinical trials.
Leisha A. Emens, MD, PhD (Johns Hopkins University
School of Medicine) presented results indicating that
the multikinase inhibitor sorafenib reverses the suppres-
sion of IL-12 and enhancement of IL-10 by PGE2 in
murine macrophages. Further, sorafenib appears to inhi-
bit PGE2-induced IL-10 secretion, indirectly preventing
STAT3 activation. Moreover, in murine macrophages,
sorafenib inhibits p38 MAPK activation, thereby pre-
venting MSK1 activation. Dr. Emens concluded that sor-
afenib impacts the cytokine profile of macrophages by
an ERK-independent mechanism.
Michael P. Gustafson, PhD (Mayo Clinic) discussed
the loss of HLA-DR expression on CD14
+ cells as a
common marker of immunosuppression in cancer
patients. Dr. Gustafson suggested that immunopheno-
typing (via flow cytometry and multiparameter analysis)
will be extremely important in characterizing patients’
baseline immunity. He argued that a bioinformatics
approach will likely reveal new relationships among
immune cells. He noted that CD14
+HLA-DR
lo/neg
monocytes are elevated in all cancer types analyzed and
that these monocytes inhibit T cell proliferation and
cannot fully mature into potent DCs. Thus, he suggested
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+HLA-DR
lo/neg monocytes
and other phenotypes may be prognostic, independent
of therapy, and may help identify potential responders/
non-responders among patients receiving cancer vac-
cines or other immunotherapies.
Weiping Zou, MD, PhD (University of Michigan) pre-
sented on polyfunctional Tregs in the microenviron-
ments of cancer and inflammation. While Foxp3
+CD4
+
regulatory T cells have been shown to inhibit immune
responses and to temper inflammation, IL-17
+CD4
+ T
(Th17) cells have been shown to mediate inflammatory
processes of autoimmune diseases. Compartmentaliza-
tion and trafficking of Treg and Th17 cells may be tis-
sue- and/or organ-specific. This selective retention and
trafficking is mediated by expression of distinct chemo-
kine receptors and integrins. Upon trafficking to periph-
eral environments, the phenotype/development of T cell
subsets (e.g., Treg, Th17 and Th1 cells) may be highly
modulated, with environmental stimuli contributing to
the plasticity of T cell development.
Dr. Zou reported on a poorly defined, minor IL-17
+
Foxp3
+CD4
+ T cell population observed in human per-
ipheral blood. This Treg subset selectively accumulates
in the colitic microenvironment and associated colon
carcinoma and has a phenotype and cytokine profile
that overlaps with Th17 and Treg cells. Induction of
these cells from memory CCR6
+ T or Treg cells is
dependent on myeloid antigen presenting cells, IL-2 and
TGFb. This subset suppressed T cell activation and sti-
mulated production of inflammatory cytokine in colitic
tissues. Moreover, these cells strongly expressed IL-8
and promoted trafficking of neutrophils. Dr. Zou con-
cluded that IL-8
+ and IL-17
+Foxp3
+ cells may represent
au n i q u e“inflammatory” Treg population that contri-
butes to the pathogenesis of ulcerative colitis, mechanis-
tically linking chronic inflammation to development of
colon cancer.
Immune Cell Trafficking to Tumor
Microenvironment
Incoming SITC president, Thomas F. Gajewski, MD,
PhD (University of Chicago) and Elizabeth M. Jaffee,
MD (Johns Hopkins University) co-chaired a session on
trafficking of immune cells to the tumor microenviron-
ment. Dr. Gajewski presented on regulation of anti-
tumor immunity through migration of subsets of
immune cells within the tumor microenvironment. Dr.
Gajewski and colleagues have explored the relationship
between the accumulation of CD8
+ Tc e l l sa n dt h ep r e -
s e n c eo fi m m u n ei n h i b i t o r yp a t h w a y sw i t h i nt h et u m o r
microenvironment. While it was generally assumed that
the tumor establishes an immune suppressive microen-
vironment to inhibit infiltrating T cells, Dr. Gajewski
has observed higher expression of immune inhibitory
pathways in tumors that contain T cells. This has led to
a new hypothesis in which the expression of IDO and
PD-L1, and the accumulation of Tregs, is dependent
upon the infiltration of CD8
+ T cells in the tumor site.
These might be induced by specific factors produced by
activated CD8
+ T cells.
A number of key factors in the tumor microenviron-
ment associated with immune-mediated tumor control
depend on regulated recruitment of subsets of inflam-
matory cells. This includes the priming phase (CD8a
+
DC recruitment), the effector phase (CD8
+ effector cell
recruitment) and negative regulation (Treg recruitment).
Understanding these factors should advance the devel-
opment of new interventions to modify the microenvir-
onment and better support T cell-mediated tumor
rejection.
David W. Mullins, PhD (University of Virginia) dis-
cussed data demonstrating spatial and temporal regula-
tion of CXCR3 chemokine production and CD8 T cell
infiltration in the metastatic melanoma tumor microen-
vironment. Dr. Mullins reviewed results demonstrating
that CXCR3 plays a key role in the infiltration of innate
and adaptive effector cells into melanoma. Moreover,
early-stage and late-stage tumors are differentially sus-
ceptible to infiltration and elimination by CD8
+ T effec-
tor cells due to temporal dysregulation of IFN-g-induced
chemokine production. He concluded that modulation
of the tumor microenvironment to create and/or main-
tain a local chemotactic gradient may improve the ther-
apeutic efficacy of cancer vaccines or adoptive transfer
immunotherapies.
Elizabeth M. Jaffee, MD (Johns Hopkins University)
presented on regulatory T cells and their role in the
tumor microenvironment. Most T cell responses to anti-
gen-specific cancer vaccines are weak and do not effec-
tively control tumor growth. In many cases this may
reflect T cell tolerance to the specific tumor antigen and
highlights the need to better understand the context of
tumor antigens to develop effective interventions that
can reverse the tolerance and improve response of these
T cells to the tumor. Dr. Jaffee and colleagues have
described immune tolerance in the HER-2/neu trans-
genic (neu-N) mouse model of breast cancer and have
used this model to explore mechanisms that suppress
high avidity antigen-specific CD8
+ T cells. Dr. Jaffee and
colleagues have previously reported that CD8
+ Tc e l l s
specific for the immunodominant neu epitope,
RNEU420-429, were observed only in neu-N mice that
had been treated with cyclophosphamide + vaccine and
rejected tumor challenge, but not in neu-N mice that
had received vaccine alone. Moreover, high avidity
RNEU420-429-specific CD8
+ T cells were also observed in
vaccine-treated mice that had been previously depleted
of CD25
+ Tregs. Dr. Jaffee’s team has developed
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for the same RNEU420-429 epitope. Using these mice, they
evaluated differences in tumor-trafficking and function
between high and low avidity cancer antigen-targeted T
cells. Dr. Jaffee described a subset of Tregs that block
trafficking and activation of high avidity T cells in neu-
expressing tumors based on adoptive transfer of naïve T
cells from these mice into tumor bearing neu-N mice.
Dr. Jaffee also described current cancer vaccine inves-
tigations of mesothelin as a T cell target in patients with
pancreatic cancer. She reported that vaccination of pan-
creatic cancer patients with two genetically-modified
pancreatic tumor cell lines induced T cell responses
against new pancreatic tumor antigens. While elevated
mesothelin expression by the tumor correlated with
shorter DFS after surgery, mesothelin-specific T cell
responses in 60 patients who received the vaccine after
surgery corresponded to improved DFS.
Arianna Calcinotto (San Raffaele Scientific Institute)
presented data demonstrating that NGR-TNF, a selec-
tive vessel-targeting agent, increases the therapeutic
potential of chemo-immunotherapy. NGR-TNF is a
novel hybrid molecule composed of TNF fused to
NGR–a peptide with the capacity to target tumor blood
vessels and to affect their physiology via CD13. Vascular
targeting with this agent enhances the therapeutic index
of active and adoptive immunotherapies. Results pre-
sented indicate that combination strategies incorporat-
ing active immunotherapy, vascular targeting with NGR-
TNF and chemotherapy are synergistic in a mouse
model of melanoma. NGR-TNF led to a temporal and
selective activation of tumor endothelial cells that over-
expressed adhesion molecules. Following treatment with
NGR-TNF, activated CD8
+ T cells rapidly and selec-
tively infiltrated the tumor, maintaining their effector
functions within the tumor environment.
iSBTc/SITC Biomarkers Task Force Update
Lisa H. Butterfield, PhD (University of Pittsburgh) pro-
vided an update on the 2009 iSBTc-FDA-NCI Workshop
on Prognostic and Predictive Immunologic Biomarkers in
Cancer. The program focused on the unique issues related
to immunologic monitoring assays as well as novel meth-
odologies for assessing the immune landscape in cancer.
Standardization of assays, assay validation, and appropriate
potency assays were the subject of one subcommittee,
while the other assessed the clinical utility of promising
novel technologies and discussed recommendations on
how to incorporate them into the clinical arena. Since the
2009 Workshop the iSBTc Biomarkers Task Force has
prepared a publication with recommendations [1] and the
society hosted a Symposium on Immuno-Oncology Bio-
markers on September 30, 2010 to explore issues related
to biomarkers in cancer immunotherapy [2]. Presentation
slides and other information about this Immuno-Oncology
Biomarkers Symposium are available on the society’sw e b -
site [3].
Cancer Immunotherapy Trials Network Update
At a special session, William Merritt, PhD (NCI)
announced Martin “Mac” Cheever, MD (Fred Hutchin-
son Cancer Research Center, University of Washington)
as the recipient of the U01 grant that will fund the Can-
cer Immunotherapy Trials Network (CITN). In addition
to this first public announcement, Dr. Merritt discussed
the application process for the clinical immunotherapy
member sites. Dr. Cheever reviewed the vision for the
CITN to provide a highly collaborative structure to effi-
ciently develop innovative, intelligent and biologically
dictated immunotherapy regimens. Dr. Cheever sum-
marized the overall strategy of the network to design,
develop and conduct important trials not otherwise pos-
sible. Under Dr. Cheever’s leadership the CITN can be
expected to 1) develop regimens that prospectively and
predictably greatly increase the number of T cells speci-
fic for known and defined antigens; 2) develop “off the
shelf” regimens that can be used by multiple investiga-
tors in multiple circumstances to serve as the backbone
for further immunotherapy agent development; and 3)
focus on agents, antigens and regimens that have
received consensus prioritization in previous workshops.
25
th Anniversary and Awards
At its 25
th Anniversary and Awards Reception that was
hosted at the Smithsonian National Museum of Natural
History on October 3, 2010, iSBTc/SITC was proud to
honor a number of leading research teams and indivi-
dual investigators who have made significant contribu-
tions to the field of cancer immunotherapy. These
accomplishments and awards have been previously sum-
marized and are reviewed on the society’s website [4].
Adoptive T Cell Transfer: The Next Wave
Patrick Hwu, MD (University of Texas, MD Anderson
Cancer Center) and Ton N. Schumacher, PhD (Nether-
lands Cancer Institute) co-chaired the final session on
adoptive T cell transfer. Malcolm K. Brenner, MD, PhD
(Baylor College of Medicine) presented on improving the
efficacy and safety of genetically modified virus-specific T
cells for solid tumors. Dr. Brenner demonstrated that
EBV-specific CTLs can be modified to express chimeric
antigen receptors (CAR) against solid tumors and that
these CAR-CTLs can survive long term and produce clini-
cal response in neuroblastoma, even in the absence of lym-
phoablation. Dr. Brenner discussed extending this
approach beyond neuroblastoma. He summarized findings
that indicate that safety of this approach may be enhanced
by incorporation of the fast-acting suicide gene icasp9.
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Cancer Research, NIH) described how functional repro-
gramming of the tumor stroma by IL-12-engineered T
cells is required for anti-tumor immunity. Dr. Kerkar
presented results from a mouse model that indicate that
small numbers of tumor-specific T cells that overproduce
IL-12 within the tumor microenvironment can eradicate
large, established B16 melanoma tumors. Moreover, anti-
tumor immunity was shown to be dependent on IL-12
and IFN-g-dependent sensitization of host bone marrow-
derived myeloid cells. Further, Dr. Kerkar demonstrated
that T cells engineered to express IL-12 induce functional
changes in the myeloid cell populations that reside within
tumors. Dr. Kerkar concluded that anti-tumor immunity
appears largely dependent on the ability of endogenous
cells to cross-present tumor antigens in vivo.
Pallavi Raja Manuri, PhD (University of Texas, MD
Anderson Cancer Center) presented on noninvasive posi-
tron emission tomography (PET) imaging of Sleeping
Beauty (SB) modified CD19-specific T cells expressing
herpes simplex virus1-thymidine kinase (HSV1-tk).
Dr. Manuri argued that to improve the design, applica-
tion and evaluation of adoptive T cell therapy monitoring
methods are required that can detect, locate and serially
quantify the cell-mediated immune responses. While cur-
rent monitoring methods (e.g., histology, flow cytometry,
Q-PCR and/cytokine analysis) are generally invasive tech-
niques, PET by contrast is noninvasive. PET can provide
accurate, sensitive whole-body imaging and allows repeti-
tive measurement in vivo. Dr. Manuri and colleagues
achieved co-expression of a CD19-specific CAR and
HSV1-tk by SB transposition. These SB modified
CD19CAR
+TK
+ T cells allowed spatio-temporal visuali-
zation by mPET using
18F-FEAU. Ablation of transferred
T cells was achieved with ganciclovir. The cells were
shown to have the capacity to kill CD19
+ tumor targets.
Ton N. Schumacher, PhD (Netherlands Cancer Insti-
tute) discussed dissection of therapy-induced melanoma-
reactive cytotoxic T cell responses. Dr. Schumacher
reported on the development and validation of technol-
ogy for high-throughout detection of melanoma-specific
T cell reactivity induced by immunotherapy. T cell
responses in TIL cell products were found to be diverse,
biased towards melanoma differentiation antigens
(MDA) and C/G antigens, and highly variable between
patients. Additionally, in ‘young TIL’,t h ei n d i v i d u a lT
cell responses were generally of low magnitude. Dr. Schu-
macher noted that T cell responses in TIL cell products
predict immune reactivity post-therapy. There was no
evidence of epitope spreading.
Matthias Stephen, MD, PhD (Massachusetts Institute
of Technology) discussed therapeutic cell engineering
using surface-conjugated synthetic nanoparticles.
Approaches to enhance persistence and functionality of
transferred T cells are desired to improve adoptive cell
therapies for cancer treatment. Dr. Stephen described an
adoptive T cell therapy strategy that involved ex vivo
conjugation of cytokine-loaded nanoparticles to T cells.
These nanoparticles remained on the cell surface of the
transferred T cells and did not interfere with trafficking
to the tumor or effector cell functions. Upon transfer, T
cells carrying the cytokine-loaded nanoparticles prolifer-
ated in vivo and provided a robust anti-tumor response.
The cytokine-loaded nanoparticles provide a pseudo-
autocrine stimulation of the transferred T cells, enabling
the use of minimal cytokine doses that have no thera-
peutic effect when delivered systemically in a soluble
form. Dr. Stephen reported that the strategy is generaliz-
able for use with a wide range of cytoreagents to mini-
mize systemic side effects.
Patrick Hwu, MD (University of Texas, MD Anderson
Cancer Center) discussed results of an ongoing Phase II
clinical trial of adoptive cell therapy with TIL in patients
with metastatic melanoma regardless of HLA subtype.
In this trial, autologous TIL were expanded and trans-
ferred back to the patient following lymphodepletion.
Adoptive transfer was followed by two cycles of high
dose IL-2 treatment. Thirty-one patients with stage IIIc-
IV melanoma and a broad range of HLA subtypes were
treated with this approach, infusing 8 x10
9 to 1.5 × 10
11
TILs. TILs were successfully expanded in 65% of cases
and in vitro anti-tumor activity was observed in 70%.
Clinical response (RECIST) was evaluated at weeks 6
and 12, and every 3 to 4 months thereafter. Dr. Hwu
reported that of the 31 patients treated, 16 (52%) had a
clinical response with one complete response and 15
partial responses. The clinical response correlated with
the total number of TILs infused, with higher numbers
associated with positive responses. Responders had
higher numbers and longer persistence of dominant
TCR clones. Dr. Hwu presented data that suggest emer-
ging T cell clones may contribute to delayed clinical
responses. The probability of a clinical response corre-
lated with higher percent and number of CD8
+ TILs
infused and with lower numbers CD4
+ TILs infused.
Moreover, the differentiation status of the CD8
+ TILs
infused correlated with clinical response, with positive
responses correlating most strongly with CD8
+ T effec-
tors cells (CD45RA
- CD62L
- CD27
-). Interestingly,
Dr. Hwu observed that expression of the negative costi-
mulation molecule “B and T lymphocyte attenuator”
(BTLA) on CD8
+ TIL was a better predictor of positive
clinical response than PD-1. These observations led to
the conclusion that the role of BTLA may depend on
the context of expression and differ based on the differ-
entiation state of the T cells. Dr. Hwu reported that
there was no difference in relative telomere length of the
infused TIL between responders and non-responders. He
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observed a high clinical response rate with adoptive cell
therapy of metastatic melanoma. CD8
+ TILs appear
essential in shrinking tumor, and TIL differentiation sta-
tus and phenotype predict clinical response better than
telomere length. Additionally, the observation that some
patients experience delayed clinical responses following a
period of stable disease suggests that additional therapies
that compromise function or survival of T cells should
not be performed until there is clear evidence of disease
progression.
Conclusion
In conclusion, the 25
th Annual Meeting of iSBTc/SITC
included dynamic presentations, interactive panel discus-
sions and scientific posters on timely topics in cancer
immunotherapy as well as valuable information on clinical
trial design and regulatory issues to advance collaboration
and translation of cancer immunotherapies. In addition to
the many exciting oral presentations, investigators from
around the globe presented more than 180 posters detail-
ing important scientific advances in various areas related
to tumor immunology and cancer immunotherapy. These
abstracts have been published and are available from the
society’s website, as are webinars of selected presentations
of the scientific sessions [5]. With many recent advances
in tumor immunology and cancer immunotherapy, as
demonstrated by the innovative basic and translational
research presented at this meeting, we look forward to the
26
th SITC Annual Meeting in North Bethesda, MD,
November 3 - 6, 2011, which will explore the following
topics: biology and application of dendritic cells; immunol-
ogy of cancer stem cells and epithelial-to-mesenchymal
transition (EMT); uncoupling negative regulation in the
tumor microenvironment; genetically engineered receptors
and adoptive cell therapies; characterization of inflamma-
tory infiltrates in human cancers; state of the art animal
models and veterinary applications for cancer and immu-
nology; high throughput technologies for immune moni-
toring and prostate cancer as a learning model. Research
will also be presented in poster format on the following
topics: therapeutic monoclonal antibodies in cancer;
immunotherapy combinations; innate immunity in cancer;
tumor vasculature, chemokines and lymphocyte trafficking
to the tumor; and targeted therapies and anti-tumor
immunity. By promoting interaction and scientific
exchange over these important topics, SITC strives to
accelerate collaboration, research and clinical translation
of immunotherapies that will improve the outcomes of
patients with cancer.
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